$761 Million is the total value of Broadfin Capital, LLC's 50 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PETX | ARATANA THERAPEUTICS INC | $25,030,000 | +5.0% | 4,083,135 | 0.0% | 3.29% | -6.2% | |
BDSI | BIODELIVERY SCIENCES INTL IN | $16,188,000 | +32.1% | 4,375,066 | 0.0% | 2.13% | +18.0% | |
REPH | RECRO PHARMA INC | $14,541,000 | -0.1% | 2,048,025 | 0.0% | 1.91% | -10.8% | |
IART | INTEGRA LIFESCIENCES HLDGS C | $8,865,000 | -31.5% | 196,572 | 0.0% | 1.17% | -38.8% | |
SLGL | SOL GEL TECHNOLOGIES | $5,103,000 | -19.7% | 847,700 | 0.0% | 0.67% | -28.3% | |
LIVN | LIVANOVA PLC | $4,665,000 | -26.2% | 51,000 | 0.0% | 0.61% | -34.1% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
RETROPHIN INC | 23 | Q3 2019 | 7.0% |
ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2022-03-22 |
4 | 2022-02-15 |
4 | 2022-01-31 |
4 | 2021-11-22 |
4 | 2021-11-15 |
4 | 2021-11-09 |
4 | 2021-08-10 |
4 | 2021-05-13 |
SC 13G/A | 2021-01-04 |
SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.